Navigation Links
VisEn Launches New VivoTag(R) 680 XL Fluorescence Molecular Imaging Label
Date:3/11/2010

BEDFORD, Mass., March 11 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new VivoTag® 680 XL fluorescent dye for labeling biomolecules in a broad range of in vitro and in vivo imaging applications.  

VisEn's new near-infrared label, VivoTag® 680 XL, adds an additional imaging label to its current portfolio of VivoTag fluorescent dyes which are used to label specific biomolecules and ligands of interest in a wide variety of in vivo and in vitro imaging applications.  The new VivoTag 680 XL is designed for more efficient labeling of target molecules under standard research conditions, and is optimized for in vivo and cell-based imaging performance, including superior brightness, biocompatibility and stability in biologic environments.  The new VivoTag 680 XL is particularly well suited for labeling of non-quenching, targeted or physiologic agents, and imaging in related applications.  The fluorescence wavelength is matched for biological imaging applications on a range of in vitro and in vivo fluorescence systems, including the VisEn FMT 2500™ LX quantitative tomography system, which also has expanded wavelength capabilities to enable simultaneous imaging of up to four agents and different biomarkers of interest in vivo.


'/>"/>
SOURCE VisEn Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
2. VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE
3. VisEn Acquires Key Fluorescence Agent Intellectual Property Portfolio and Technology Platforms From Bayer Schering Pharma
4. VisEn Launches New Cat B 680 FAST(TM) Fluorescence Molecular Imaging Agent
5. VisEn Launches New Cat B 750 Fast(TM) Fluorescence Molecular Imaging Agent at American Heart Association Meeting
6. VisEn Launches New OsteoSense(R) 800 and VivoTag(R) 800 Fluorescence Molecular Imaging Agents
7. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
8. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
9. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... GENEVA, Ill. , Jan. 15, 2014 The ... a Medical Fitness Center by the Medical Fitness Association, ... centers to achieve their full potential. The Cadence Fitness ... in the western suburbs and second in the Chicagoland ...
(Date:1/15/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ...
(Date:1/15/2014)... Jan. 15, 2014  A novel wearable injector slightly larger than ... for patients to self-inject prescription drugs in the large doses ... blood diseases, autoimmune deficiencies, and genetic disorders.  ... $220B by 2018, according to analysts.   Many of these drugs ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... Inc. (Nasdaq: OPTR ) announced today the ... 3 trials in patients with Clostridium difficile ... Infectious Disease Society of America (IDSA) in Vancouver, British ... M.D., of the University of Oxford, presented combined data ...
... PARK, Kan., Oct. 22 Mid*Lands IRB, LLC is ... by the Association for the Accreditation of Human Research ... Council on Accreditation.   Located in the ... board (IRB) that protects the rights and welfare of ...
Cached Medicine Technology:Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 2Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 3Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 4Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 5Mid*Lands IRB, LLC - First Independent IRB in Kansas and the Kansas City Area Awarded Accreditation for Protecting Research Participants 2
(Date:7/10/2014)... Alba,s research at the University of Huddersfield could help ... popular emulsion-based food products such as butter, mayonnaise, ... to gain an international profile for her work. , ... science at the University and now she has embarked ... supervisor, Dr Vassilis Kontogiorgos, she is investigating the potential ...
(Date:7/10/2014)... says the human brain operates much the same whether ... provide a better understanding of schizophrenia, bipolar disorder and ... 13.6 million Americans. , In newly published research in ... professor at the Center for Molecular and Behavioral Neuroscience, ... at rest is basically the same as that of ...
(Date:7/10/2014)... at sarcomas research group at the Bellvitge Biomedical Research ... have been tested in 19 patients a new therapeutic ... which indicate that the new treatment could stabilize the ... in the British Journal of Cancer ., ... and complex since there are several subtypes. It can ...
(Date:7/10/2014)... 10, 2014) Men who experience hot flashes are ... find relief from their silent suffering if they ... findings from a Baylor University case study., After seven ... had uncontrolled hot flashes following prostate cancer surgery showed ... also an impressive improvement in sleep quality, according to ...
(Date:7/9/2014)... of low back pain are not linked to weather ... and precipitation. Findings published in Arthritis Care & ... Rheumatology (ACR), indicate that the risk of low back ... gusts, but was not clinically significant. , According ... low back pain at some point in their life, ...
Breaking Medicine News(10 mins):Health News:World interest in research work on the benefits of the Okra plant 2Health News:Working to loosen the grip of severe mental illness 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Low back pain? Don't blame the weather 2
... die hard chocó fans could crack open a bar of ... its true colors and bares// its heart! When you melt ... a new finding. ,Researchers in the United ... an 18-month study to gauge the influence of aspirin on ...
... – whether from holiday feasts or rich desserts or alcoholic ... ,Heartburn – generally caused by naturally occurring acids ... by a characteristic burning sensation that sufferers describe as rolling ... in this process. ,“Most of the time heartburn ...
... The health crisis triggered by the death of over ... health institution's laboratory, has prompted Panamanian President// Martin Torrijos ... ,Torrijos said that the government had since ... Security Body (CSS), permanently in a bid to win ...
... A report released in the state of Pennsylvania, U.S,reveals that ... there in 2005.// ,The report the ... kind in various hospitals spread all over the state released ... have contracted hospital acquired infections when admitted there for some ...
... The genes of progeny are dependant on a fairly ... is potent enough to impact the genes of the ... consumed by expectant mice were seen to impact generation ... the National Academy of Sciences., ,To quote the ...
... Paris- Scientists from the Mecca of Fashion, Paris, have ... presence of a natural chemical called opiorphin//, a natural ... morphine., ,In their experiments, rodents were found to ... chemical in comparison with the usual dosage of morphine. ...
Cached Medicine News:Health News:Holiday Season Could Ring in “Heartburn Season 2Health News:Holiday Season Could Ring in “Heartburn Season 3Health News:Hospital infections gaining ground in Pennsylvania hospitals 2
... Intended for the quantitative determination ... Reaction: kinetic, lag phase of ... by linear phase of at ... nm. Linearity: 100 mg/dL (35.6 ...
For the quantitative determination of Urea Nitrogen in serum. Linearity: 80 mg/dl. Reaction measured at 340 nm....
Intended for the quantitative determination of total bilirubin in serum. Modified evelynmalloy method. Endpoint reaction. Wavelength: 555 nm. Linearity: 20 mg/dl (340 mol/l)...
... Powerwave is the first microplate spectrophotometer designed ... 7 days per week. With rugged hardware, ... Powerwave breaks the barrier of traditional spectrophotometry ... One instrument can easily read up to ...
Medicine Products: